ArticleWorld journal of surgical oncology2025
The impact of sequential chemoradiotherapy versus concurrent chemoradiotherapy on prognosis in adjuvant treatment after radical hysterectomy for cervical cancer.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to compare the efficacy and toxicity of sequential chemoradiotherapy (SCRT) versus concurrent chemoradiotherapy (CCRT) in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer.
methodsA retrospective analysis was conducted on 236 patients who underwent radical hysterectomy for cervical cancer in our gynecology, oncology, and radiotherapy departments from February 2018 to January 2022. Patients were divided into two groups based on their postoperative adjuvant treatment: the SCRT group (n = 112) and the CCRT group (n = 124). Follow-up evaluations were conducted over a period of 3 years. Patient data, including demographic characteristics, cancer characteristics, efficacy, toxicity assessment, and survival outcomes, were collected through the medical record system.
resultsSignificant differences were noted in grade 3–4 treatment-related toxicities, with CCRT showing higher rates of leucopenia (P = 0.003) and nausea/vomiting (P = 0.003). In terms of survival outcomes, while overall survival rates were similar between the two groups, the CCRT group demonstrated significantly better progression-free survival (PFS) (34.89 ± 3.76 months vs. 33.58 ± 5.42 months, P = 0.033) compared to the SCRT group. CCRT is associated with better PFS but also higher rates of severe leucopenia and nausea/vomiting. Multivariate analysis identified CCRT (Hazard Ratio [HR] = 0.522), well-differentiated tumor grading (HR = 0.535), early-stage disease (FIGO stage I) (HR = 0.322), and better performance status (ECOG score of 0) (HR = 0.266) as independent protective factors against shorter PFS (P < 0.05).
conclusionIn the adjuvant treatment after radical hysterectomy for cervical cancer, CCRT is associated with better PFS but also higher rates of severe leucopenia and nausea/vomiting. CCRT may offer a therapeutic advantage in delaying disease progression and extending survival times, despite its increased toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.